Literature DB >> 18027223

Statistical analysis for two-stage seamless design with different study endpoints.

Shein-Chung Chow1, Qingshu Lu, Siu-Keung Tse.   

Abstract

In the pharmaceutical industry, it is desirable to apply an adaptive seamless trial design to combine two separate clinical studies that are normally conducted for achieving separate objectives such as a Phase II study for dose finding and a Phase III confirmatory study for efficacy. As a result, an adaptive seamless Phase II/III trial design consisting of two phases, namely a learning phase and a confirmatory phase, is commonly considered in pharmaceutical development. In some cases, however, the study endpoints for the two separate studies may be different due to long treatment duration. In this case, test statistics for the final analysis based on the combined data are necessary developed. In this paper, a test statistic utilizing data collected from both phases is proposed assuming that there is a well established relationship between the two different study endpoints. Formula for sample size calculation based on the proposed test statistic is derived. Sample size allocation at the two phases is also discussed.

Mesh:

Year:  2007        PMID: 18027223     DOI: 10.1080/10543400701645249

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

1.  Seamless Phase IIa/IIb and enhanced dose-finding adaptive design.

Authors:  Jiacheng Yuan; Herbert Pang; Tiejun Tong; Dong Xi; Wenzhao Guo; Peter Mesenbrink
Journal:  J Biopharm Stat       Date:  2015-09-21       Impact factor: 1.051

Review 2.  Adaptive designs for randomized trials in public health.

Authors:  C Hendricks Brown; Thomas R Ten Have; Booil Jo; Getachew Dagne; Peter A Wyman; Bengt Muthén; Robert D Gibbons
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

3.  Adaptive design clinical trials: Methodology, challenges and prospect.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

Review 4.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Andrea L Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

Review 5.  Adaptive design methods in clinical trials - a review.

Authors:  Shein-Chung Chow; Mark Chang
Journal:  Orphanet J Rare Dis       Date:  2008-05-02       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.